| Year |
Citation |
Score |
| 2024 |
Xu L, Peng F, Luo Q, Ding Y, Yuan F, Zheng L, He W, Zhang SS, Fu X, Liu J, Mutlu AS, Wang S, Nehring RB, Li X, Tang Q, ... ... Ellis MJ, et al. IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer. Cell. PMID 39419025 DOI: 10.1016/j.cell.2024.09.032 |
0.549 |
|
| 2024 |
Chen A, Kim BJ, Mitra A, Vollert CT, Lei JT, Fandino D, Anurag M, Holt MV, Gou X, Pilcher JB, Goetz MP, Northfelt DW, Hilsenbeck SG, Marshall CG, Hyer ML, ... ... Ellis MJ, et al. PKMYT1 is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Molecular Cancer Therapeutics. PMID 38781103 DOI: 10.1158/1535-7163.MCT-23-0564 |
0.354 |
|
| 2023 |
Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, ... ... Ellis MJ, et al. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 41: 4192-4199. PMID 37672882 DOI: 10.1200/JCO.22.02511 |
0.308 |
|
| 2023 |
Wang J, Saltzman AB, Jaehnig EJ, Lei JT, Malovannaya A, Holt MV, Young MN, Rimawi MF, Ademuyiwa FO, Anurag M, Kim BJ, Ellis MJ. Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins. Cancer Research Communications. 3: 1551-1563. PMID 37587913 DOI: 10.1158/2767-9764.CRC-22-0501 |
0.317 |
|
| 2023 |
Lei JT, Jaehnig EJ, Smith H, Holt MV, Li X, Anurag M, Ellis MJ, Mills GB, Zhang B, Labrie M. The Breast Cancer Proteome and Precision Oncology. Cold Spring Harbor Perspectives in Medicine. PMID 37137501 DOI: 10.1101/cshperspect.a041323 |
0.364 |
|
| 2023 |
Gou X, Kim BJ, Anurag M, Lei JT, Young MN, Holt MV, Fandino D, Vollert CT, Singh P, Alzubi MA, Malovannaya A, Dobrolecki LE, Lewis MT, Li S, Foulds CE, ... Ellis MJ, et al. Kinome reprogramming is a targetable vulnerability in ESR1 fusion-driven breast cancer. Cancer Research. PMID 37071495 DOI: 10.1158/0008-5472.CAN-22-3484 |
0.318 |
|
| 2023 |
Hunt KK, Suman VJ, Wingate HF, Leitch AM, Unzeitig G, Boughey JC, Meric-Bernstam F, Ellis MJ, Olson J. Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer. Annals of Surgical Oncology. PMID 36653664 DOI: 10.1245/s10434-022-12972-5 |
0.308 |
|
| 2022 |
Anurag M, Jaehnig EJ, Krug K, Lei JT, Bergstrom EJ, Kim BJ, Vashist TD, Tran Huynh AM, Dou Y, Gou X, Huang C, Shi Z, Wen B, Korchina V, Gibbs RA, ... ... Ellis MJ, et al. Proteogenomic markers of chemotherapy resistance and response in triple negative breast cancer. Cancer Discovery. PMID 36001024 DOI: 10.1158/2159-8290.CD-22-0200 |
0.317 |
|
| 2022 |
Kalra R, Chen CH, Wang J, Salam AB, Dobrolecki LE, Lewis A, Sallas C, Yates CC, Gutierrez C, Karanam B, Anurag M, Lim B, Ellis MJ, Kavuri SM. Poziotinib inhibits HER2 mutant-driven therapeutic resistance and multi-organ metastasis in breast cancer. Cancer Research. PMID 35736563 DOI: 10.1158/0008-5472.CAN-21-3106 |
0.332 |
|
| 2022 |
Eteleeb AM, Thunuguntla PK, Gelev KZ, Tang CY, Rozycki EB, Miller A, Lei JT, Jayasinghe RG, Dang HX, White NM, Reis-Filho JS, Mardis ER, Ellis MJ, Ding L, Silva-Fisher JM, et al. LINC00355 regulates p27 expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer. Npj Breast Cancer. 8: 49. PMID 35418131 DOI: 10.1038/s41523-022-00412-2 |
0.329 |
|
| 2022 |
Ma CX, Luo J, Freedman RA, Pluard TJ, Nangia JR, Lu J, Valdez-Albini F, Cobleigh M, Jones JM, Lin NU, Winer EP, Marcom PK, Anderson J, Thomas S, Haas B, ... ... Ellis MJ, et al. The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2 mutated, non-amplified metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35046057 DOI: 10.1158/1078-0432.CCR-21-3418 |
0.311 |
|
| 2021 |
Ademuyiwa FO, Chen I, Luo J, Rimawi MF, Hagemann IS, Fisk B, Jeffers G, Skidmore ZL, Basu A, Richters M, Ma CX, Weilbaecher K, Davis J, Suresh R, Peterson LL, ... ... Ellis MJ, et al. Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. Breast Cancer Research and Treatment. PMID 34173924 DOI: 10.1007/s10549-021-06307-3 |
0.327 |
|
| 2021 |
Punturi NB, Seker S, Devarakonda V, Mazumder A, Kalra R, Chen CH, Li S, Primeau T, Ellis MJ, Kavuri SM, Haricharan S. Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer. Nature Communications. 12: 2940. PMID 34011995 DOI: 10.1038/s41467-021-23271-0 |
0.328 |
|
| 2021 |
Watt AC, Cejas P, DeCristo MJ, Metzger-Filho O, Lam EYN, Qiu X, BrinJones H, Kesten N, Coulson R, Font-Tello A, Lim K, Vadhi R, Daniels VW, Montero J, Taing L, ... ... Ellis MJ, et al. CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nature Cancer. 2: 34-48. PMID 33997789 DOI: 10.1038/s43018-020-00135-y |
0.335 |
|
| 2021 |
Bado IL, Zhang W, Hu J, Xu Z, Wang H, Sarkar P, Li L, Wan YW, Liu J, Wu W, Lo HC, Kim IS, Singh S, Janghorban M, Muscarella AM, ... ... Ellis MJ, et al. The bone microenvironment increases phenotypic plasticity of ER breast cancer cells. Developmental Cell. 56: 1100-1117.e9. PMID 33878299 DOI: 10.1016/j.devcel.2021.03.008 |
0.308 |
|
| 2021 |
Wang X, Veeraraghavan J, Liu CC, Cao X, Qin L, Kim JA, Tan Y, Loo SK, Hu Y, Lin L, Lee S, Shea M, Mitchell T, Li S, Ellis MJ, et al. Therapeutic targeting of nemo-like kinase in primary and acquired endocrine-resistant breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33542078 DOI: 10.1158/1078-0432.CCR-20-2961 |
0.334 |
|
| 2021 |
Bowling EA, Wang JH, Gong F, Wu W, Neill NJ, Kim IS, Tyagi S, Orellana M, Kurley SJ, Dominguez-Vidaña R, Chung HC, Hsu TY, Dubrulle J, Saltzman AB, Li H, ... ... Ellis MJ, et al. Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. Cell. PMID 33450205 DOI: 10.1016/j.cell.2020.12.031 |
0.561 |
|
| 2020 |
Guo Z, Primeau T, Luo J, Zhang C, Sun H, Hoog J, Gao F, Huang S, Edwards DP, Davies SR, Aft R, Ding L, Ellis MJ, Li S, Ma CX. Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models. Cancers. 12. PMID 33371187 DOI: 10.3390/cancers12123857 |
0.326 |
|
| 2020 |
Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, Kreipe HH, Laenkholm AV, Pan H, Penault-Llorca FM, Polley MY, et al. Assessment of Ki67 in Breast Cancer: Updated Recommendations from the International Ki67 in Breast Cancer Working Group. Journal of the National Cancer Institute. PMID 33369635 DOI: 10.1093/jnci/djaa201 |
0.318 |
|
| 2020 |
Dustin D, Gu G, Beyer AR, Herzog SK, Edwards DG, Lin H, Gonzalez TL, Grimm SL, Coarfa C, Chan DW, Kim BJ, De La O JP, Ellis MJ, Liu D, Li S, et al. RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. British Journal of Cancer. PMID 33257837 DOI: 10.1038/s41416-020-01174-z |
0.357 |
|
| 2020 |
Krug K, Jaehnig EJ, Satpathy S, Blumenberg L, Karpova A, Anurag M, Miles G, Mertins P, Geffen Y, Tang LC, Heiman DI, Cao S, Maruvka YE, Lei JT, Huang C, ... ... Ellis MJ, et al. Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell. PMID 33212010 DOI: 10.1016/j.cell.2020.10.036 |
0.401 |
|
| 2020 |
Cairns J, Ingle JN, Dudenkov TTM, Kalari KR, Carlson EE, Na J, Buzdar AU, Robson ME, Ellis MJ, Goss PE, Shepherd LE, Goodnature B, Goetz MP, Weinshilboum RM, Li H, et al. Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action. Jci Insight. PMID 32701512 DOI: 10.1172/Jci.Insight.137571 |
0.352 |
|
| 2020 |
Reinert T, Ramalho S, de Vasconcelos VCA, Silva LR, da Silva AER, de Andrade CA, Kraft MBPL, Coelho GP, Mandelli J, Binotto M, Cabello C, de Paiva Silva GR, Bines J, Barrios CH, Ellis MJ, et al. Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy. Frontiers in Oncology. 10: 342. PMID 32309212 DOI: 10.3389/fonc.2020.00342 |
0.3 |
|
| 2020 |
Zheng ZY, Anurag M, Lei JT, Cao J, Singh P, Peng J, Kennedy H, Nguyen NC, Chen Y, Lavere P, Li J, Du XH, Cakar B, Song W, Kim BJ, ... ... Ellis MJ, et al. Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer. Cancer Cell. PMID 32142667 DOI: 10.1016/J.Ccell.2020.02.003 |
0.35 |
|
| 2020 |
Ingle JN, Cairns J, Suman VJ, Shepherd LE, Fasching PA, Hoskin TL, Singh RJ, Desta Z, Kalari KR, Ellis MJ, Goss PE, Chen BE, Volz B, Barman P, Carlson EE, et al. Anastrozole has an association between degree of estrogen suppression and outcomes in early breast cancer and is a ligand for estrogen receptor α. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32098767 DOI: 10.1158/1078-0432.Ccr-19-3091 |
0.309 |
|
| 2020 |
Satpathy S, Jaehnig EJ, Krug K, Kim BJ, Saltzman AB, Chan DW, Holloway KR, Anurag M, Huang C, Singh P, Gao A, Namai N, Dou Y, Wen B, Vasaikar SV, ... ... Ellis MJ, et al. Microscaled proteogenomic methods for precision oncology. Nature Communications. 11: 532. PMID 31988290 DOI: 10.1038/S41467-020-14381-2 |
0.331 |
|
| 2019 |
Anurag M, Zhu M, Huang C, Vasaikar S, Wang J, Hoog J, Burugu S, Gao D, Suman V, Zhang XH, Zhang B, Nielsen T, Ellis MJ. Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance). Journal of the National Cancer Institute. PMID 31665365 DOI: 10.1093/Jnci/Djz213 |
0.343 |
|
| 2019 |
Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, Wagner LI, Kaklamani VG, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer DL, Brufsky AM, ... ... Ellis MJ, et al. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. Jama Oncology. PMID 31566680 DOI: 10.1001/Jamaoncol.2019.4794 |
0.328 |
|
| 2019 |
Pu M, Messer K, Davies SR, Vickery TL, Pittman E, Parker BA, Ellis MJ, Flatt SW, Marinac CR, Nelson SH, Mardis ER, Pierce JP, Natarajan L. Research-based PAM50 signature and long-term breast cancer survival. Breast Cancer Research and Treatment. PMID 31542876 DOI: 10.1007/s10549-019-05446-y |
0.323 |
|
| 2019 |
Cheng AS, Leung SCY, Gao D, Burugu S, Anurag M, Ellis MJ, Nielsen TO. Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort. Breast Cancer Research and Treatment. PMID 31522348 DOI: 10.1007/s10549-019-05438-y |
0.333 |
|
| 2019 |
Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, ... ... Ellis MJ, et al. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. The New England Journal of Medicine. PMID 31157962 DOI: 10.1056/Nejmoa1904819 |
0.309 |
|
| 2019 |
Lei JT, Gou X, Seker S, Ellis MJ. alterations and metastasis in estrogen receptor positive breast cancer. Journal of Cancer Metastasis and Treatment. 5. PMID 31106278 DOI: 10.20517/2394-4722.2019.12 |
0.365 |
|
| 2019 |
Bellon JR, Guo H, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Hudis CA, et al. Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Research and Treatment. PMID 31004299 DOI: 10.1007/S10549-019-05238-4 |
0.304 |
|
| 2018 |
Lei JT, Gou X, Ellis MJ. fusions drive endocrine therapy resistance and metastasis in breast cancer. Molecular & Cellular Oncology. 5: e1526005. PMID 30525098 DOI: 10.1080/23723556.2018.1526005 |
0.351 |
|
| 2018 |
Matsunuma R, Chan DW, Kim BJ, Singh P, Han A, Saltzman AB, Cheng C, Lei JT, Wang J, Roberto da Silva L, Sahin E, Leng M, Fan C, Perou CM, Malovannaya A, ... Ellis MJ, et al. DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 30498031 DOI: 10.1073/Pnas.1810598115 |
0.366 |
|
| 2018 |
Kim J, Piao HL, Kim BJ, Yao F, Han Z, Wang Y, Xiao Z, Siverly AN, Lawhon SE, Ton BN, Lee H, Zhou Z, Gan B, Nakagawa S, Ellis MJ, et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nature Genetics. PMID 30349115 DOI: 10.1038/S41588-018-0252-3 |
0.379 |
|
| 2018 |
Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R, ... ... Ellis MJ, et al. Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Reports. 24: 1434-1444.e7. PMID 30089255 DOI: 10.1016/J.Celrep.2018.07.009 |
0.307 |
|
| 2018 |
Reinert T, de Paula B, Shafaee MN, Souza PH, Ellis MJ, Bines J. Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer. Chinese Clinical Oncology. 7: 25. PMID 30056727 DOI: 10.21037/cco.2018.06.06 |
0.372 |
|
| 2018 |
Nguyen TM, Kabotyanski EB, Dou Y, Reineke LC, Zhang P, Zhang XH, Malovannaya A, Jung SY, Mo Q, Roarty KP, Chen Y, Zhang B, Neilson JR, Lloyd RE, Perou CM, ... Ellis MJ, et al. FGFR1-activated Translation of WNT Pathway Components with Structured 5' UTRs is Vulnerable to Inhibition of EIF4A-dependent Translation Initiation. Cancer Research. PMID 29844125 DOI: 10.1158/0008-5472.Can-18-0631 |
0.518 |
|
| 2018 |
Gates LA, Gu G, Chen Y, Rohira AD, Lei JT, Hamilton RA, Yu Y, Lonard DM, Wang J, Wang SP, Edwards DG, Lavere PF, Shao J, Yi P, Jain A, ... ... Ellis MJ, et al. Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets. Oncogene. PMID 29748621 DOI: 10.1038/S41388-018-0284-2 |
0.302 |
|
| 2018 |
Reinert T, Gonçalves R, Ellis MJ. Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer. Current Treatment Options in Oncology. 19: 23. PMID 29663173 DOI: 10.1007/s11864-018-0538-9 |
0.334 |
|
| 2018 |
Nair A, Chung HC, Sun T, Tyagi S, Dobrolecki LE, Dominguez-Vidana R, Kurley SJ, Orellana M, Renwick A, Henke DM, Katsonis P, Schmitt E, Chan DW, Li H, Mao S, ... ... Ellis MJ, et al. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nature Medicine. PMID 29578538 DOI: 10.1038/Nm.4507 |
0.331 |
|
| 2018 |
Mundt F, Rajput S, Li S, Ruggles KV, Mooradian AD, Mertins P, Gillette MA, Krug K, Guo Z, Hoog J, Erdmann-Gilmore P, Primeau T, Huang S, Edwards DP, Wang X, ... ... Ellis MJ, et al. Mass spectrometry-based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3K inhibitors in triple negative breast cancers. Cancer Research. PMID 29472518 DOI: 10.1158/0008-5472.Can-17-1990 |
0.31 |
|
| 2017 |
Doostan I, Karakas C, Kohansal M, Low KH, Ellis MJ, Olson JA, Suman V, Hunt K, Moulder-Thompson S, Keyomarsi K. Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28947566 DOI: 10.1158/1078-0432.Ccr-17-1544 |
0.338 |
|
| 2017 |
Ma CX, Suman V, Goetz MP, Northfelt DW, Burkard ME, Ademuyiwa F, Naughton MJ, Margenthaler J, Aft R, Gray RJ, Tevaarwerk AJ, Wilke LG, Haddad TC, Moynihan T, Loprenzi C, ... ... Ellis MJ, et al. A Phase II trial of neoadjuvant MK2206, an AKT inhibitor, with anastrozole in clinical stage 2 or 3 PIK3CA mutant ER positive and HER2 negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28874413 DOI: 10.1158/1078-0432.Ccr-17-1260 |
0.34 |
|
| 2017 |
Haricharan S, Punturi N, Singh P, Holloway KR, Anurag M, Schmelz J, Schmidt C, Lei JT, Suman V, Hunt K, Olson JA, Hoog J, Li S, Huang S, Edwards DP, ... ... Ellis MJ, et al. Loss of MutL Disrupts Chk2-dependent Cell Cycle Control Through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. Cancer Discovery. PMID 28801307 DOI: 10.1158/2159-8290.Cd-16-1179 |
0.357 |
|
| 2017 |
Ellis MJ. Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer. Breast (Edinburgh, Scotland). PMID 28669712 DOI: 10.1016/j.breast.2017.06.039 |
0.346 |
|
| 2017 |
Zhang X, Kim S, Hundal J, Herndon JM, Li S, Petti AA, Soysal SD, Li L, McLellan MD, Hoog J, Primeau T, Myers N, Vickery TL, Sturmoski M, Hagemann IS, ... ... Ellis MJ, et al. Breast cancer neoantigens can induce CD8 T cell responses and antitumor immunity. Cancer Immunology Research. PMID 28619968 DOI: 10.1158/2326-6066.Cir-16-0264 |
0.353 |
|
| 2017 |
Goncalves R, DeSchryver K, Ma C, Tao Y, Hoog J, Cheang M, Crouch E, Dahiya N, Sanati S, Barnes M, Sarian LOZ, Olson J, Allred DC, Ellis MJ. Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer. Breast Cancer Research and Treatment. PMID 28612227 DOI: 10.1007/s10549-017-4329-y |
0.314 |
|
| 2017 |
Goncalves R, Reinert T, Ellis MJ. Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017730424. PMID 28581884 DOI: 10.1200/JCO.2017.73.0424 |
0.308 |
|
| 2017 |
Niravath P, Cakar B, Ellis M. Current Challenges Associated With Next-Generation Sequencing of Breast Cancer-Reply. Jama Oncology. PMID 28520826 DOI: 10.1001/jamaoncol.2017.0665 |
0.301 |
|
| 2017 |
Shafaee MN, Ellis MJ. Breast Cancer Patient-Derived Xenografts: Pros, Cons, and Next Steps. Journal of the National Cancer Institute. 109. PMID 28376181 DOI: 10.1093/jnci/djw307 |
0.326 |
|
| 2017 |
Ma CX, Gao F, Luo J, Northfelt DW, Goetz MP, Forero A, Hoog J, Naughton MJ, Ademuyiwa F, Suresh R, Anderson KS, Margenthaler J, Aft R, Hobday TJ, Moynihan T, ... ... Ellis MJ, et al. NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28270497 DOI: 10.1158/1078-0432.Ccr-16-3206 |
0.338 |
|
| 2017 |
Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, Jiang H, Hu J, Xu F, Zhao Y, Liu L, Fernandez-Salas E, Xu J, Dou Y, Wen B, ... ... Ellis MJ, et al. Targeted degradation of BET proteins in triple-negative breast cancer. Cancer Research. PMID 28209615 DOI: 10.1158/0008-5472.Can-16-2622 |
0.373 |
|
| 2017 |
Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, et al. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016694406. PMID 28045625 DOI: 10.1200/Jco.2016.69.4406 |
0.315 |
|
| 2016 |
Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, et al. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Reviews. PMID 28025748 DOI: 10.1007/S10555-016-9653-X |
0.319 |
|
| 2016 |
Robertson JF, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, ... ... Ellis MJ, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet (London, England). PMID 27908454 DOI: 10.1016/S0140-6736(16)32389-3 |
0.302 |
|
| 2016 |
Lu J, McEachern D, Li S, Ellis MJ, Wang S. Reactivation of p53 by MDM2 inhibitor MI-77301 for the treatment of endocrine-resistant breast cancer. Molecular Cancer Therapeutics. PMID 27765850 DOI: 10.1158/1535-7163.Mct-16-0028 |
0.341 |
|
| 2016 |
Ingle JN, Xie F, Ellis MJ, Goss PE, Shepherd LE, Chapman JW, Chen BE, Kubo M, Furukawa Y, Momozawa Y, Stearns V, Pritchard KI, Barman P, Carlson EE, Goetz MP, et al. Genetic polymorphisms in the long noncoding RNA MIR2052HG offer a pharmacogenomic basis for the response of breast cancer patients to aromatase inhibitor therapy. Cancer Research. PMID 27758888 DOI: 10.1158/0008-5472.Can-16-1371 |
0.367 |
|
| 2016 |
Miller CA, Gindin Y, Lu C, Griffith OL, Griffith M, Shen D, Hoog J, Li T, Larson DE, Watson M, Davies SR, Hunt K, Suman VJ, Snider J, Walsh T, ... ... Ellis MJ, et al. Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. Nature Communications. 7: 12498. PMID 27502118 DOI: 10.1038/Ncomms12498 |
0.305 |
|
| 2016 |
Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, Wang X, Qiao JW, Cao S, Petralia F, Kawaler E, Mundt F, Krug K, Tu Z, Lei JT, ... ... Ellis MJ, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 534: 55-62. PMID 27251275 DOI: 10.1038/Nature18003 |
0.337 |
|
| 2016 |
Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B, Forero-Torres A, Lee SC, de Boer R, Petrakova K, Vallentin S, Perez EA, Piccart M, ... Ellis M, et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Oncology. PMID 27155741 DOI: 10.1016/S1470-2045(16)00106-6 |
0.34 |
|
| 2016 |
Ma CX, Bose R, Ellis MJ. Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer. Advances in Experimental Medicine and Biology. 882: 125-54. PMID 26987533 DOI: 10.1007/978-3-319-22909-6_5 |
0.336 |
|
| 2016 |
Haricharan S, Lei J, Ellis M. Mammary Ductal Environment Is Necessary for Faithful Maintenance of Estrogen Signaling in ER(+) Breast Cancer. Cancer Cell. 29: 249-250. PMID 26977876 DOI: 10.1016/j.ccell.2016.02.017 |
0.355 |
|
| 2016 |
Chimge NO, Little GH, Baniwal SK, Adisetiyo H, Xie Y, Zhang T, O'Laughlin A, Liu ZY, Ulrich P, Martin A, Mhawech-Fauceglia P, Ellis MJ, Tripathy D, Groshen S, Liang C, et al. RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancer. Nature Communications. 7: 10751. PMID 26916619 DOI: 10.1038/Ncomms10751 |
0.336 |
|
| 2016 |
Ma CX, Sanchez C, Gao F, Crowder R, Naughton M, Pluard T, Creekmore A, Guo Z, Hoog J, Lockhart AC, Doyle A, Erlichman C, Ellis MJ. A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor Positive Metastatic Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26783290 DOI: 10.1158/1078-0432.CCR-15-2160 |
0.343 |
|
| 2015 |
Ben-Baruch NE, Bose R, Kavuri SM, Ma CX, Ellis MJ. HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 1061-4. PMID 26358790 DOI: 10.6004/Jnccn.2015.0131 |
0.347 |
|
| 2015 |
Wardell SE, Ellis MJ, Alley HM, Eisele K, VanArsdale T, Dann SG, Arndt KT, Primeau T, Griffin E, Shao J, Crowder RJ, Lai JP, Norris JD, McDonnell DP, Li S. Efficacy of SERD/SERM Hybrid-CDK4/6 inhibitor combinations in models of endocrine therapy resistant breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 25991817 DOI: 10.1158/1078-0432.Ccr-15-0360 |
0.337 |
|
| 2015 |
Cheang MC, Martin M, Nielsen TO, Prat A, Voduc D, Rodriguez-Lescure A, Ruiz A, Chia S, Shepherd L, Ruiz-Borrego M, Calvo L, Alba E, Carrasco E, Caballero R, Tu D, ... ... Ellis MJ, et al. Defining breast cancer intrinsic subtypes by quantitative receptor expression. The Oncologist. 20: 474-82. PMID 25908555 DOI: 10.1634/Theoncologist.2014-0372 |
0.308 |
|
| 2015 |
Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. The New England Journal of Medicine. 372: 134-41. PMID 25564897 DOI: 10.1056/Nejmoa1406281 |
0.336 |
|
| 2015 |
Xu Z, Wu C, Xie F, Slysz GW, Tolic N, Monroe ME, Petyuk VA, Payne SH, Fujimoto GM, Moore RJ, Fillmore TL, Schepmoes AA, Levine DA, Townsend RR, Davies SR, ... ... Ellis M, et al. Comprehensive quantitative analysis of ovarian and breast cancer tumor peptidomes. Journal of Proteome Research. 14: 422-33. PMID 25350482 DOI: 10.1021/Pr500840W |
0.329 |
|
| 2014 |
Goncalves R, Warner WA, Luo J, Ellis MJ. New concepts in breast cancer genomics and genetics. Breast Cancer Research : Bcr. 16: 460. PMID 25606588 DOI: 10.1186/s13058-014-0460-4 |
0.34 |
|
| 2014 |
Barbie TU, Alexe G, Aref AR, Li S, Zhu Z, Zhang X, Imamura Y, Thai TC, Huang Y, Bowden M, Herndon J, Cohoon TJ, Fleming T, Tamayo P, Mesirov JP, ... ... Ellis MJ, et al. Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. The Journal of Clinical Investigation. 124: 5411-23. PMID 25365225 DOI: 10.1172/Jci75661 |
0.377 |
|
| 2014 |
Ellis MJ. HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy. Journal of the National Cancer Institute. 106. PMID 25139535 DOI: 10.1093/jnci/dju212 |
0.326 |
|
| 2014 |
Ellis MJ. Mutational analysis of breast cancer: guiding personalized treatments. Breast (Edinburgh, Scotland). S19-21. PMID 24074785 DOI: 10.1016/j.breast.2013.07.003 |
0.346 |
|
| 2013 |
Ma CX, Ellis MJ. The Cancer Genome Atlas: clinical applications for breast cancer. Oncology (Williston Park, N.Y.). 27: 1263-9, 1274-9. PMID 24624545 |
0.306 |
|
| 2013 |
Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig G, Royce M, McCall LM, Ewer MS, Hunt KK. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. The Lancet. Oncology. 14: 1317-25. PMID 24239210 DOI: 10.1016/S1470-2045(13)70502-3 |
0.324 |
|
| 2013 |
Ademuyiwa FO, Ellis MJ, Ma CX. Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer. Journal of Oncology. 2013: 219869. PMID 23983689 DOI: 10.1155/2013/219869 |
0.329 |
|
| 2013 |
Won JR, Gao D, Chow C, Cheng J, Lau SY, Ellis MJ, Perou CM, Bernard PS, Nielsen TO. A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 26: 1438-50. PMID 23702728 DOI: 10.1038/Modpathol.2013.97 |
0.359 |
|
| 2013 |
Xu S, Li S, Guo Z, Luo J, Ellis MJ, Ma CX. Combined targeting of mTOR and AKT Is an effective strategy for basal-like breast cancer in patient-derived xenograft models Molecular Cancer Therapeutics. 12: 1665-1675. PMID 23689832 DOI: 10.1158/1535-7163.MCT-13-0159 |
0.405 |
|
| 2013 |
Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Johnson DB, Tozer R, D'Souza DP, Chalchal H, Spadafora S, Stearns V, Perez EA, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1398-404. PMID 23358971 DOI: 10.1200/JCO.2012.44.7805 |
0.318 |
|
| 2013 |
Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discovery. 3: 27-34. PMID 23319768 DOI: 10.1158/2159-8290.Cd-12-0462 |
0.37 |
|
| 2012 |
Bastien RR, RodrÃguez-Lescure Ã, Ebbert MT, Prat A, Munárriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Ãlvarez I, Dowell T, Wall D, Seguà MÃ, Barley L, ... ... Ellis MJ, et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. Bmc Medical Genomics. 5: 44. PMID 23035882 DOI: 10.1186/1755-8794-5-44 |
0.306 |
|
| 2012 |
Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 486: 353-60. PMID 22722193 DOI: 10.1038/Nature11143 |
0.318 |
|
| 2012 |
Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M. A common language in neoadjuvant breast cancer clinical trials: Proposals for standard definitions and endpoints The Lancet Oncology. 13: e240-e248. PMID 22652232 DOI: 10.1016/S1470-2045(11)70378-3 |
0.303 |
|
| 2012 |
Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade FO, Nanda R, Hoffman PC, Naughton MJ, Pluard T, Conzen SD, Ellis MJ. Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Research and Treatment. 136: 355-63. PMID 22245973 DOI: 10.1007/S10549-011-1910-7 |
0.322 |
|
| 2012 |
Chimge NO, Baniwal SK, Luo J, Coetzee S, Khalid O, Berman BP, Tripathy D, Ellis MJ, Frenkel B. Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 901-11. PMID 22147940 DOI: 10.1158/1078-0432.Ccr-11-1530 |
0.348 |
|
| 2012 |
Prat A, Ellis MJ, Perou CM. Practical implications of gene-expression-based assays for breast oncologists. Nature Reviews. Clinical Oncology. 9: 48-57. PMID 22143140 DOI: 10.1038/Nrclinonc.2011.178 |
0.336 |
|
| 2012 |
Ma CX, Luo J, Ellis MJ. Molecular profiling of triple negative breast cancer. Breast Disease. 32: 73-84. PMID 21778575 DOI: 10.3233/BD-2010-0309 |
0.339 |
|
| 2011 |
Peddi PF, Ellis MJ, Ma C. Molecular basis of triple negative breast cancer and implications for therapy. International Journal of Breast Cancer. 2012: 217185. PMID 22295242 DOI: 10.1155/2012/217185 |
0.372 |
|
| 2011 |
Roop RP, Ma CX, Ellis MJ. PARP inhibitors and their evolving role in breast cancer. Oncology (Williston Park, N.Y.). 25: 1033-4. PMID 22106554 |
0.34 |
|
| 2011 |
Van Tine BA, Crowder RJ, Ellis MJ. ER and PI3K independently modulate endocrine resistance in ER-positive breast cancer. Cancer Discovery. 1: 287-8. PMID 22096658 DOI: 10.1158/2159-8290.CD-11-0192 |
0.365 |
|
| 2011 |
Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. Journal of the National Cancer Institute. 103: 1656-64. PMID 21960707 DOI: 10.1093/jnci/djr393 |
0.338 |
|
| 2011 |
Ma CX, Crowder RJ, Ellis MJ. Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors. Steroids. 76: 750-2. PMID 21420991 DOI: 10.1016/j.steroids.2011.02.023 |
0.388 |
|
| 2011 |
Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, Lin L, Ellis MJ. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Research : Bcr. 13: R21. PMID 21362200 DOI: 10.1186/bcr2833 |
0.333 |
|
| 2010 |
Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5222-32. PMID 20837693 DOI: 10.1158/1078-0432.Ccr-10-1282 |
0.311 |
|
| 2010 |
Perou CM, Parker JS, Prat A, Ellis MJ, Bernard PS. Clinical implementation of the intrinsic subtypes of breast cancer. The Lancet. Oncology. 11: 718-9; author reply . PMID 20688274 DOI: 10.1016/S1470-2045(10)70176-5 |
0.312 |
|
| 2010 |
Chawla JS, Ma CX, Ellis MJ. Neoadjuvant endocrine therapy for breast cancer. Surgical Oncology Clinics of North America. 19: 627-38. PMID 20620931 DOI: 10.1016/j.soc.2010.04.004 |
0.308 |
|
| 2009 |
Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, Snider J, Davies SR, Swiatek PJ, Cottingham S, Watson MA, Ellis MJ, Sigler RE, Furge KA, Vande Woude GF. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 106: 12909-14. PMID 19567831 DOI: 10.1073/pnas.0810403106 |
0.389 |
|
| 2009 |
Toi M, Sasano H, Ellis MJ. [Future prospects of neoadjuvant endocrine therapy in postmenopausal breast cancer]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 36: 1035-42. PMID 19542732 |
0.345 |
|
| 2009 |
Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Journal of the National Cancer Institute. 101: 736-50. PMID 19436038 DOI: 10.1093/Jnci/Djp082 |
0.349 |
|
| 2009 |
Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L, Snider J, Davies SR, Olson JA, Watson MA, Saporita A, ... ... Ellis MJ, et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Research. 69: 3955-62. PMID 19366795 DOI: 10.1158/0008-5472.Can-08-4450 |
0.376 |
|
| 2009 |
Ma CX, Sanchez CG, Ellis MJ. Predicting endocrine therapy responsiveness in breast cancer. Oncology (Williston Park, N.Y.). 23: 133-42. PMID 19323294 |
0.349 |
|
| 2009 |
Tebbit CL, Zhai J, Untch BR, Ellis MJ, Dressman HK, Bentley RC, Baker JA, Marcom PK, Nevins JR, Marks JR, Olson JA. Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Research and Treatment. 118: 635-43. PMID 19224362 DOI: 10.1007/S10549-008-0301-1 |
0.309 |
|
| 2009 |
Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, ... ... Ellis MJ, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1160-7. PMID 19204204 DOI: 10.1200/Jco.2008.18.1370 |
0.307 |
|
| 2008 |
Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. Journal of the National Cancer Institute. 100: 1380-8. PMID 18812550 DOI: 10.1093/jnci/djn309 |
0.335 |
|
| 2007 |
Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Research and Treatment. 33-43. PMID 17912634 DOI: 10.1007/s10549-007-9701-x |
0.353 |
|
| 2007 |
Ellis MJ, Dixon M, Dowsett M, Nagarajan R, Mardis E. A luminal breast cancer genome atlas: progress and barriers. The Journal of Steroid Biochemistry and Molecular Biology. 106: 125-9. PMID 17826627 DOI: 10.1016/J.Jsbmb.2007.05.011 |
0.315 |
|
| 2007 |
Mullins M, Perreard L, Quackenbush JF, Gauthier N, Bayer S, Ellis M, Parker J, Perou CM, Szabo A, Bernard PS. Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues. Clinical Chemistry. 53: 1273-9. PMID 17525107 DOI: 10.1373/Clinchem.2006.083725 |
0.316 |
|
| 2006 |
Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N, Mann G, Tao Y, Ellis MJ. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Research and Treatment. 102: 43-9. PMID 16897431 DOI: 10.1007/s10549-006-9307-8 |
0.32 |
|
| 2006 |
Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4218-24. PMID 16857794 DOI: 10.1158/1078-0432.CCR-05-2821 |
0.319 |
|
| 2006 |
Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3019-25. PMID 16754938 DOI: 10.1200/JCO.2005.04.3034 |
0.308 |
|
| 2005 |
Crowder RJ, Ellis MJ. Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway. Breast Cancer Research : Bcr. 7: 212-4. PMID 16168140 DOI: 10.1186/bcr1307 |
0.369 |
|
| 2005 |
Ellis MJ. Neoadjuvant endocrine therapy for breast cancer: more questions than answers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4842-4. PMID 15998901 DOI: 10.1200/JCO.2005.92.003 |
0.328 |
|
| 2004 |
Crowder RJ, Lombardi DP, Ellis MJ. Successful targeting of ErbB2 receptors-is PTEN the key? Cancer Cell. 6: 103-4. PMID 15324690 DOI: 10.1016/j.ccr.2004.08.001 |
0.332 |
|
| 2004 |
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. The New England Journal of Medicine. 351: 781-91. PMID 15317891 DOI: 10.1056/NEJMoa040766 |
0.332 |
|
| 2004 |
Ellis M, Ballman K. Trawling for genes that predict response to breast cancer adjuvant therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2267-9. PMID 15136594 DOI: 10.1200/JCO.2004.03.950 |
0.303 |
|
| 2004 |
Wong ZW, Ellis MJ. Neoadjuvant endocrine therapy for breast cancer: An overlooked option? Oncology. 18: 411-420. PMID 15134351 |
0.314 |
|
| 2004 |
Dougherty MK, Schumaker LM, Jordan VC, Welshons WV, Curran EM, Ellis MJ, El-Ashry D. Estrogen receptor expression and sensitivity to paclitaxel in breast cancer. Cancer Biology & Therapy. 3: 460-7. PMID 15020841 DOI: 10.4161/Cbt.3.5.810 |
0.342 |
|
| 2004 |
Ellis MJ. Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy. Annals of Surgical Oncology. 11: 9S-17S. PMID 15015704 DOI: 10.1007/BF02524790 |
0.308 |
|
| 2004 |
Ellis MJ. Neoadjuvant endocrine therapy as a drug development strategy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 391S-5S. PMID 14734497 DOI: 10.1158/1078-0432.CCR-031202 |
0.317 |
|
| 2004 |
Come SE, Buzdar AU, Arteaga CL, Bissell MJ, Brown MA, Ellis MJ, Goss PE, Green JE, Ingle JN, Lee AV, Medina D, Nicholson RI, Santen RJ, Schiff R, Hart CS. Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 327S-330S. PMID 14734487 DOI: 10.1158/1078-0432.Ccr-031213 |
0.318 |
|
| 2004 |
Wong ZW, Phillips SJ, Ellis MJ. Dramatic Response of Choroidal Metastases from Breast Cancer to a Combination of Trastuzumab and Vinorelbine Breast Journal. 10: 54-56. PMID 14717761 DOI: 10.1111/j.1524-4741.2004.09614.x |
0.339 |
|
| 2004 |
Ellis MJ. Breast cancer gene expression analysis--the case for dynamic profiling. Advances in Experimental Medicine and Biology. 532: 223-34. PMID 12908561 |
0.347 |
|
| 2004 |
Dowsett M, Ellis MJ. Role of biologic markers in patient selection and application to disease prevention. American Journal of Clinical Oncology. 26: S34-9. PMID 12902875 DOI: 10.1097/00000421-200308001-00006 |
0.361 |
|
| 2003 |
Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Jänicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, Miller WR. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Research. 63: 6523-31. PMID 14559846 |
0.333 |
|
| 2002 |
Shaw HS, Ellis MJ. Letrozole in the treatment of breast cancer. Expert Opinion On Pharmacotherapy. 3: 607-17. PMID 11996638 DOI: 10.1517/14656566.3.5.607 |
0.337 |
|
| Show low-probability matches. |